casirivimab-imdevimab
Selected indexed studies
- Casirivimab/Imdevimab: First Approval. (Drugs, 2021) [PMID:34716907]
- Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19. (Med Lett Drugs Ther, 2021) [PMID:34544100]
- Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019. (Am J Perinatol, 2024) [PMID:35973799]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Casirivimab/Imdevimab: First Approval. (2021) pubmed
- Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19. (2021) pubmed
- Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019. (2024) pubmed
- Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. (2022) pubmed
- Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19. (2022) pubmed
- Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant. (2022) pubmed
- Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors. (2022) pubmed
- Casirivimab - Imdevimab in Covid 19 - Early Indian experience. (2022) pubmed
- Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study. (2023) pubmed
- Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19. (2023) pubmed